T. Rowe Price Investment Management
CCCC icon

T. Rowe Price Investment Management’s C4 Therapeutics CCCC Stock Holding History

T. Rowe Price Investment Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-547,667
Closed -$4.8M – 546
2022
Q3 		$4.8M Buy
+547,667
New +$5.69M ﹤0.01% 526

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management's CCCC Position: Q4 2022 in Review

T. Rowe Price Investment Management sold out of C4 Therapeutics (CCCC) in Q4 2022, closing a stake of 547,667 shares — an estimated $4.8M sold.

T. Rowe Price Investment Management first reported a position in CCCC in Q3 2022 and held it in 1 quarter. The position peaked at $4.8M in Q3 2022. 117 funds tracked by Wall St. Rank hold CCCC as of Q4 2022.

  • T. Rowe Price Investment Management reported no remaining C4 Therapeutics position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 547,667 C4 Therapeutics shares in Q4 2022, an estimated $4.8M.
  • T. Rowe Price Investment Management first reported a position in C4 Therapeutics in Q3 2022 and held it in 1 quarter.
  • T. Rowe Price Investment Management's C4 Therapeutics position peaked at $4.8M in Q3 2022.
  • 117 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2022.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.